712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)
oleh: David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.